Almac Acquires Arran Chemical Company and Expands Biocatalysis Services

Almac Acquires Arran Chemical Company and Expands Biocatalysis Services

Craigavon, N.I., UK, - 03 November 2015 - Almac Group, the global contract development and manufacturing organisation, today announced the acquisition of 100% shares of Arran Chemical Company, an independent and privately owned organisation based in Athlone, Ireland. 

The addition of Arran Chemical Company marks a new chapter in Almac's continuous growth, with significant increase in scale (a range of reactors up to 6,300L and total capacity of up to 45m3) the new combined business will integrate Biocatalysis technology with large scale intermediates manufacture.

Located in County Roscommon, just two hours away from Almac Group's Headquarters, the existing Arran Chemical Company specialises in the manufacture of products for the pharmaceutical, flavour/fragrance, personal care and other specialised chemical and industrial applications. Both companies have more than 25 years' experience and have been working together closely on multiple projects over the past 5 years.

The bespoke facility offers a full range of scales including kg lab, multi-purpose pilot plant and manufacturing plant. Arran's assets strongly complements Almac Sciences' existing business and will allow both entities to continue growing in their respective market. 

"This is a very exciting opportunity for both Almac and Arran Chemical Company." said Dr Stephen Barr, Managing Director, Almac Sciences. "Based on our combined strength, scale and technology, we will offer commercial products and pharmaceutical intermediates using our current world leading Biocatalysis technology platform enabling us to address our global clients' growing demands for a high quality, integrated, efficient service and we are delighted to be able to support our clients in this way."

Anthony Owens, Managing Director, Arran Chemical Company commented "We are very pleased with this significant development which enables us to continue to deliver high quality products to our global customer base in addition to offering a broader range of solutions.  This move builds on our established presence in the industry and we look forward to merging our expertise and experience with Almac's undoubted success to match the increasing requirements of customers across the whole spectrum of the industry."

About Almac Group

'Partnering to Advance Human Health'

The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally. The services range from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.

The international company is a privately owned organisation that has organically grown over 30 years and now employs in excess of 3,700 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations in the UK, across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).

Reg. Office: 20 Seagoe Industrial Estate, Craigavon,

BT63 5QD, United Kingdom Reg. No: N.I. 61368 VAT Reg. No: GB 782 5804 05

Disclaimer: If you do not wish to receive further e-mails from Kerry Lyle using Meltwater or from all future e-mails from Meltwater, please click the following link: [Remove Me]. Requests will take a maximum of 2 business days to process. 

If you would like to contact Meltwater, we can be reached at: Meltwater, 225 Bush Street, Suite 1000, San Francisco, California 94104 

Almac Group

20 Seagoe Industrial Estate

Craigavon

BT63 5QD

United Kingdom
T +44 28 3839 5820
E [email protected]
www.almacgroup.com

 

 

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.